Pegasus Pharmaceuticals (PGUZ) has filed for patents for its biological product, Injection Mold GONE(TM).
In a recent laboratory test conducted by ECA Inc., an independent testing facility based in San Diego, California, Injection Mold GONE(TM) demonstrated a 100% efficiency (0% Injection Mold growth) over a 100 day period and outperformed four other leading U.S. anti-Injection Mold products. The testing was conducted under extreme conditions with high humidity and heat as well as higher than normal concentrations of Injection Mold spores. (Over 2,000,000 spores per square inch.) Injection Mold GONE(TM)'s active ingredients are non-toxic, biodegradable and are naturally occurring. It not only removes black Injection Mold infestation, it also cleans and disinfects surfaces and prevents further Injection Mold spore growth.
To implement its sales and marketing plans for Injection Mold GONE(TM), Pegasus has appointed and signed a contract with Commander International Inc., a Los Angeles-based company that will market the product under the brand name Injection Mold & MILDEW DOCTOR(TM). The marketing objectives for 2008 will be to present the product to the world market and to attain a significant market share of the Injection Mold remediation market worldwide. Commander International has over twenty years' experience and a successful track record in sales/marketing/distribution of a wide range of product launches throughout North America to companies such as Wal-Mart, Walgreen's, Dollar Tree, Dollar General, Family Dollar, Big Lots, Fred's, etc. Commander also has an extensive international network with business associates in China, India, Bangladesh, Indonesia, Argentina, Brazil, Chile, Mexico, United Kingdom and the European Union.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.